



Phosphorylation of ARD1 by IKK β contributes to its destabilization and degradation

Hsu-Ping Kuo^{a,b}, Dung-Fang Lee^{a,b}, Weiya Xia^a, Chien-Chen Lai^{c,d}, Long-Yuan Li^{e,f}, Mien-Chie Hung^{a,b,e,f,*}

^a Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA

^b Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX 77030, USA

^c Graduate Institute of Chinese Medical Science, China Medical University, Taichung 404, Taiwan

^d Institute of Molecular Biology, National Chung Hsing University, Taichung 402, Taiwan

^e Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University and Hospital, Taichung 404, Taiwan

^f Asia University, Taichung 413, Taiwan

ARTICLE INFO

Article history:

Received 19 August 2009

Available online 28 August 2009

Keywords:

Phosphorylation

Arrest-defective protein 1

I κ B kinase β

Destabilization

Degradation

ABSTRACT

I κ B kinase β (IKK β), a major kinase downstream of various proinflammatory signals, mediates multiple cellular functions through phosphorylation and regulation of its substrates. On the basis of protein sequence analysis, we identified arrest-defective protein 1 (ARD1), a protein involved in apoptosis and cell proliferation processes in many human cancer cells, as a new IKK β substrate. We provided evidence showing that ARD1 is indeed a *bona fide* substrate of IKK β . IKK β physically associated with ARD1 and phosphorylated it at Ser209. Phosphorylation by IKK β destabilized ARD1 and induced its proteasome-mediated degradation. Impaired growth suppression was observed in ARD1 phosphorylation-mimic mutant (S209E)-transfected cells as compared with ARD1 non-phosphorylatable mutant (S209A)-transfected cells. Our findings of molecular interactions between ARD1 and IKK β may enable further understanding of the upstream regulation mechanisms of ARD1 and of the diverse functions of IKK β .

© 2009 Elsevier Inc. All rights reserved.

Introduction

Arrest-defective protein 1 (ARD1), first identified in yeast, is the catalytic subunit of NatA acetyltransferase, responsible for N-terminal α -acetylation [1]. Mutation of *Arđ1* in yeast leads to defective entry into the stationary phase and sporulation in response to nutrient deprivation or mating pheromone α -factor [2,3]. In mammalian cells, ARD1 possesses both N-terminal α -protein and ϵ -protein acetylation activities, thus representing a novel kind of acetyltransferase [4,5]. ARD1 has been reported to mediate hypoxia-inducible factor 1 α (HIF-1 α) ubiquitination and degradation through Lys⁵³² acetylation [5]; however, several groups were unable to replicate this observation [6–8]. Another ϵ -acetylation substrate of ARD1 is β -catenin, which was shown to mediate the cell proliferation effect of ARD1 in lung cancer cells [9]. In addition to cell growth control, ARD1 is also involved in DNA damage-induced apoptosis [10]. Although ARD1 plays a critical role in regulating cell proliferation and apoptosis, the molecular mechanisms regulating ARD1 stability and functions remain largely unclear.

* Corresponding author. Address: Department of Molecular and Cellular Oncology, Unit 108, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. Fax: +1 713 794 3270.

E-mail address: mhung@mdanderson.org (M.-C. Hung).

I κ B kinase β (IKK β) is a component of the IKK complex, which contains IKK α , IKK β , and a regulatory subunit, IKK γ . When activated by proinflammatory signals such as tumor necrosis factor α (TNF α) and lipopolysaccharide (LPS), IKK β triggers the degradation of I κ B α through phosphorylation, which in turn releases and mediates the nuclear translocation of nuclear factor κ B (NF- κ B). NF- κ B then activates gene expression by binding to the target DNA sequence and thus contributing to diverse functions. Although first identified as the kinase for I κ B α , IKK β was subsequently shown to have other substrates as well. By identification of these non-I κ B α downstream substrates, more cellular functions independent of I κ B α have been found. For example, IKK β is able to phosphorylate insulin receptor substrate 1 (IRS1) to suppress insulin signaling [11]. IKK β also affects mitogen-activated protein kinase (MAPK) pathway by repressing DOK1 via phosphorylation-dependent manner and therefore increases cell migration [12,13]. Additionally, IKK β has been shown to promote breast cancer development through phosphorylation-mediated inhibition of two tumor suppressors, forkhead box O3a (FOXO3a) and tuberous sclerosis complex 1 (TSC1). IKK β triggers the degradation of FOXO3a and TSC1, thereby exerting anti-apoptosis effects [14] and promoting angiogenesis [15]. All these findings suggest that IKK β might have versatile roles in participating in physiological functions.

In the current study, we identified ARD1 as a substrate of IKK β . IKK β associated with and phosphorylated ARD1 at Ser209 *in vitro* and *in vivo*. Phosphorylation of ARD1 by IKK β decreased its stability and led to the proteasome-mediated degradation of ARD1. IKK β reduced the growth suppression effect of ARD1 through phosphorylation. We conclude that IKK β down-regulates ARD1 through phosphorylation and destabilization.

Materials and methods

Constructs. The FLAG-IKK β and FLAG-nIKK β plasmids were generated as previously described [15]. The Myc-ARD1 and HA-ARD1 plasmids were constructed by inserting the cDNA of hARD1 into the pcDNA6 and pCMV5 vectors containing the Myc and HA tags, respectively. We constructed the GST-ARD1 plasmid by subcloning the ARD1 fragment into the pGEX6P-1 GST vector. All constructs of ARD1 mutants were generated as follows. The PCR reaction was performed in a total volume of 25 μ l pfu reaction buffer containing 30 ng DNA, 0.2 mM dNTPs, 0.4 pmol of each primer, 1.5 μ l DMSO and 1 μ l pfu polymerase. Cycling conditions were 94 °C (5 min) for one cycle; 94 °C (1 min), 55 °C (1 min), and 68 °C (14 min) for 20 cycles; and a final extension of 68 °C (10 min). DpnI (1 μ l) was then added and incubated at 37 °C for 1.5 h to remove the methylated DNA. The sequences were confirmed by DNA sequencing.

Experimental reagents. We used antibodies to FLAG (F3165, Sigma, St. Louis, MO), HA (11666606001, Roche, Switzerland), Myc (11667203001, Roche), ARD1 (15-288-22667, GenWay, San Diego, CA), acetyl lysine (05-515 and 06-933, Upstate, Billerica, MA), and α -tubulin (T-5168, Sigma). Cycloheximide and MG132 were purchased from Sigma.

Cell culture. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/F12 medium supplemented with 10% fetal bovine serum (FBS). For transient transfection, cells at 50–60% confluence were transfected with DNA by SN liposome (DNA:SN = 1 μ g:1 μ l) [16]. Six hours after transfection, the DNA-liposome mixture was removed and the fresh medium was added. Cells were harvested for analysis 2 days after transfection.

Immunoprecipitation and immunoblotting assays. Immunoprecipitation and immunoblotting assays were performed as described previously [14]. Briefly, radioimmunoprecipitation assay-B (RIPA-B) buffer (1% Triton X-100, 150 mM NaCl, 20 mM Na₂PO₄, 1 mM PMSF, 3 μ g/ml aprotinin, 750 μ g/ml benzamidine, 2 mM Na₃VO₄, 5 mM NaF, pH 7.4) was used as lysis and immunoprecipitation buffers. For immunoprecipitation, specific antibodies were incubated with cell lysates at 4 °C for 16–18 h. Protein A or Protein G was then added for another 3 h. Immunoprecipitates were washed five times using RIPA-B buffer. Sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) sampling buffer was added, and the samples were boiled for 10 min. Beads were spun down, and the supernatants were loaded onto an SDS–PAGE. For immunoblotting, proteins subjected to SDS–PAGE were transferred onto polyvinylidene fluoride (PVDF) membrane pretreated with methanol. Membranes were then blocked with 5% skim milk or 1% bovine serum albumin (BSA) in Tris-buffered saline (TBS) buffer (10 mM Tris, 150 mM NaCl, pH 7.9) with 0.05% Tween 20. The indicated proteins and phosphorylation levels were analyzed by using specific antibodies. Horseradish peroxidase (HRP)–conjugated secondary antibodies and Enhanced Chemiluminescence (ECL) kit were used for detection.

In vitro kinase assays. IKK β kinase assays were performed as described previously [14,17]. Briefly, FLAG-IKK β or FLAG-nIKK β transfected cells were lysed and immunoprecipitated with anti-FLAG antibodies. IKK β kinase activity was analyzed by *in vitro* kinase assay using purified GST-ARD1 as the substrate and GST and GST-

IkB α were served as negative and positive controls, respectively. Reactions were performed at 30 °C for 30 min in a final volume of 50 μ l consisting of kinase buffer (20 mM Tris, 7.5 mM MgCl₂, 30 μ M ATP, and 10 μ Ci γ -[³²P]-ATP) and were stopped by adding 20 μ l of SDS–PAGE sampling buffer and boiling for 10 min. Reaction products were loaded on an SDS–PAGE and analyzed by autoradiography.

Identification of phosphorylation sites by mass spectrometry analysis. Cell lysate from FLAG-IKK β - and Myc-ARD1-cotransfected HEK293T cells was immunoprecipitated by anti-Myc antibodies. After separation on SDS–PAGE, protein bands corresponding to ARD1 were identified, excised from the gel, and then subjected to digestion by trypsin or other proteases. After isolation by immobilized metal affinity chromatography, the enriched phosphopeptides were analyzed by using mass spectrometry analysis.

Results and discussion

IKK β physically interacts with ARD1

Since IKK β functions as an oncoprotein and ARD1 might have a role in suppression of tumor progression, it is tempting to know whether IKK β -mediated tumor development via regulating ARD1. To examine the physical association between IKK β and ARD1, we first performed exogenous protein reciprocal coimmunoprecipitation assays. We cotransfected FLAG-IKK β and HA-ARD1 into HEK293T cells, and found the presence of HA-ARD1 in FLAG-IKK β immunoprecipitates (Fig. 1A). Consistently, FLAG-IKK β was detected in HA-ARD1 immunoprecipitates (Fig. 1A). This interaction was also observed with endogenous IKK β and ARD1 using specific antibodies to IKK β and ARD1 (Fig. 1B). Together, these results demonstrated the association between ARD1 and IKK β .

IKK β phosphorylates ARD1

Analysis of the amino acid sequence revealed an IKK β consensus motif (DS Ψ XXS/T) on ARD1 (Fig. 2A), which is present in many substrates of IKK β , for example, I κ B α , FOXO3a, and TSC1. This sequence (DSKDLS) is evolutionarily conserved from human to mouse (Fig. 2B), suggesting the importance of this region. The observation that ARD1 contains a potential IKK β phosphorylation motif prompted us to investigate whether ARD1 is a substrate of IKK β . As shown in Fig. 2C, *in vitro* kinase assay demonstrated that GST-ARD1 but not GST protein is efficiently phosphorylated by FLAG-IKK β (lanes 1 and 2, left panel). In contrast, no phosphorylation of ARD1 was observed with kinase dead FLAG-nIKK β control (lane 4, left panel). This result demonstrated that IKK β phosphorylates ARD1 *in vitro*. Because ARD1 is an acetyltransferase, we next questioned whether ARD1 could induce ϵ -acetylation of IKK β . HEK293T cells were cotransfected with ARD1 and IKK β and treated with sodium butyrate to prevent protein deacetylation. The acetylated IKK β was detected by anti-acetyl lysine antibodies. We were unable to detect any ϵ -acetylation of IKK β (data not shown), even after using two different antibodies. In summary, our results suggest that ARD1 is a physiological substrate of IKK β .

IKK β phosphorylation site is identified on ARD1

To further identify the IKK β phosphorylation site on ARD1, we cotransfected Myc-ARD1 and FLAG-IKK β plasmids into HEK293T cells and purified ARD1 protein for mass spectrometry analysis. The results demonstrated *in vivo* phosphorylation of ARD1 by IKK β at Ser209 (Fig. 3A). To demonstrate the phosphorylation is dependent on IKK β but not other IKK β -regulated Ser/Thr kinases, we performed *in vitro* kinase assays using immunoprecipitated IKK β or




Fig. 1. ARD1 physically interacted with IKKβ. (A) Exogenous interaction of ARD1 and IKKβ. HEK293T cells were cotransfected with HA-ARD1 and FLAG-IKKβ, and cell lysates were immunoprecipitated with anti-FLAG or anti-HA antibodies. The association between HA-ARD1 and FLAG-IKKβ was analyzed by reciprocal coimmunoprecipitation and immunoblotting assays. (B) Endogenous interaction of ARD1 and IKKβ in HEK293T cells. Cell lysates were immunoprecipitated with specific antibodies to ARD1 and IKKβ to identify the association of endogenous proteins.




Fig. 2. IKKβ phosphorylated ARD1 *in vitro*. (A) ARD1 contains a putative IKKβ phosphorylation motif (DSψXSS/T). D, aspartic acid; S, serine; ψ, hydrophobic amino acid; X, any amino acid. (B) IKKβ consensus motif (DSKDL) on ARD1 is conserved from human to mouse. (C) ARD1 was phosphorylated by IKKβ. FLAG-IKKβ or FLAG-nIKKβ was transfected into HEK293T cells and immunoprecipitated for *in vitro* kinase assay using GST-ARD1 as the substrate. GST and GST-IκBα proteins were used as negative and positive controls, respectively.

purified IKKβ. Substitution of Ala for Ser209 (S209A) abolished the phosphorylation of ARD1 by IKKβ immunocomplex (Fig. 3B) or purified IKKβ (Fig. 3C). Together, these results from kinase assays and mass spectrometry analysis indicate that IKKβ phosphorylates ARD1 at Ser209 *in vitro* and *in vivo*.

Phosphorylation by IKKβ decreases the stability of ARD1

We next generated ARD1 (S209E) mutant to mimic the phosphorylation by IKKβ and studied the mechanisms of ARD1 regulation by IKKβ. Since lower expression level of ARD1 (S209E) protein




Fig. 3. Identification of IKK β phosphorylation site on ARD1. (A) HEK293T cells were transfected with FLAG-IKK β and Myc-ARD1. After separation by SDS-PAGE electrophoresis, the band representing ARD1 protein was isolated and analyzed by mass spectrometry. (B) The IKK β phosphorylation site on ARD1, Ser209, was identified by *in vitro* kinase assays. Immunoprecipitated FLAG-IKK β was used in the kinase assay and kinase dead FLAG-nIKK β was served as a negative control. (C) Purified IKK β protein was incubated with GST-ARD1 (WT) and GST-ARD1 (S209A) in the kinase assay.

was observed, we first clarified whether the phosphorylation of ARD1 affects its stability. Treatment with cycloheximide to inhibit protein translation showed the decreased stability of ARD1 (S209E) (Fig. 4A) compared with that of wild-type (WT) ARD1 or ARD1 (S209A). The protein of ARD1 (S209E) was restored to a level similar to that of ARD1 (WT) or ARD1 (S209A) after MG132 treatment (Fig. 4B), suggesting that phosphorylation of ARD1 enhances its proteasome-mediated degradation. Together, these results demonstrated that phosphorylation of ARD1 by IKK β contributes to its destabilization and degradation.

Phosphorylation of ARD1 by IKK β reduced its growth suppression effect

On the basis of our observation that IKK β phosphorylates and destabilizes ARD1, we next asked whether phosphorylation by

IKK β affects the biological function of ARD1. We found ARD1 (WT)-transfected cells grow much slowly than vector control-transfected cells. In addition, expression of ARD1 non-phosphorylatable mutant (S209A) significantly inhibited cell growth of HEK293T cells as compared with ARD1 phosphorylation-mimic mutant (S209E) (Fig. 4C), suggesting phosphorylation by IKK β decreases the growth suppression function of ARD1.

Whether ARD1's function in tumorigenesis is as an oncoprotein or a tumor suppressor has remained a matter of controversy in the literature [10,18,19]. It has been reported that protein post-translational modifications may change its function, for example, IKK α phosphorylation of CREB-binding protein (CBP) determines its associated partners and the oncoprotein/tumor suppressor role [20]. In the current studies, we identified IKK β as a kinase of ARD1 that mediated its phosphorylation on Ser209, thereby resulting in the degradation of ARD1. Consider-




Fig. 4. Phosphorylation by IKK β destabilized ARD1 and reduced the growth suppression effect of ARD1. (A) Phosphorylation of ARD1 by IKK β decreased its stability as determined by treatment with cycloheximide (100 μ g/ml). The graph shows the relative intensity of various ARD1 proteins at different time points (standardized to 1 for the cycloheximide-pretreated [CHX 0 h] sample). W, WT; A, S209A; E, S209E. (B) Treatment of MG132 restored the protein expression of ARD1 (S209E) mutant. HEK293T cells were transfected with various ARD1 constructs and treated with MG132 for 6 h before analysis. W, WT; A, S209A; E, S209E. (C) Constructs of vector control, ARD1 WT and various ARD1 mutants were transfected into HEK293T cells. Cells (1×10^6) were plated 2 days after transfection and the number of cells was counted at different time points. V, vector control; W, WT; A, S209A; E, S209E. (D) A model by which phosphorylation of ARD1 by IKK β induces ARD1 degradation and decreases its growth suppression effect.

ing that IKK β has been shown an association with oncogenic activity through negatively regulating its downstream substrates, for example, TSC1 and FOXO3a [14,15], the destabilization of ARD1 by IKK β seems to favor a tumor suppressor role for ARD1. Indeed, our results showed expression of ARD1 in HEK293T cells suppresses cell growth.

In summary, we identified an upstream kinase, IKK β , which associated with and phosphorylated ARD1, resulting in its destabilization (Fig. 4D). The phosphorylation of ARD1 by IKK β reduced the growth suppression effect of ARD1. Further investigation into the biological effect of this post-translational modification may advance our knowledge of IKK β functions and may clarify the controversial role of ARD1 in the development of cancer.

Acknowledgments

We thank the Department of Scientific Publications at The University of Texas M.D. Anderson Cancer Center for editing this manuscript. This work was partially supported by National Insti-

tutes of Health (NIH) Grants R01 CA109311, CCSG CA16672, and P01 CA099031, The University of Texas M.D. Anderson SPORC Grants (P50 CA116199 for breast cancer, and P50 CA83639 for ovarian cancer), MDACC/CMUH Sister Institution Fund, Patel Memorial Breast Cancer Endowment Fund, and grants from the Kadoorie Charitable Foundations and the National Breast Cancer Foundation, Inc., to M.-C.H.; a grant from Taiwan National Science Council (NSC-96-3111-B) to L.-Y.L. and M.-C.H.; a predoctoral fellowship from the US Army Breast Cancer Research Program (Grant W81XWH-08-1-0397) and the Andrew Sowell-Wade Huggins Scholarship from The University of Texas Graduate School of Biomedical Sciences at Houston to H.-P.K.; a predoctoral fellowship from the US Army Breast Cancer Research Program (Grant W81XWH-05-1-0252) and the T.C. Hsu Endowed Memorial Scholarship, Andrew Sowell-Wade Huggins Scholarship and Presidents' Research Scholarship from The University of Texas Graduate School of Biomedical Sciences at Houston to D.-F.L.; and grants from National Health Research Institutes (NHRI-EX98-9603BC) and Department of Health (DOH98-TD-I-111-TN002) to L.-Y.L.

References

- [1] J.R. Mullen, P.S. Kayne, R.P. Moerschell, S. Tsunasawa, M. Gribskov, M. Colavito-Shepanski, M. Grunstein, F. Sherman, R. Sternglanz, Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast, *EMBO J.* 8 (1989) 2067–2075.
- [2] M. Whiteway, J.W. Szostak, The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways, *Cell* 43 (1985) 483–492.
- [3] M. Whiteway, R. Freedman, S. Van Arsdell, J.W. Szostak, J. Thorner, The yeast ARD1 gene product is required for repression of cryptic mating-type information at the HML locus, *Mol. Cell. Biol.* 7 (1987) 3713–3722.
- [4] T. Arnesen, D. Anderson, C. Baldersheim, M. Lanotte, J.E. Varhaug, J.R. Lillehaug, Identification and characterization of the human ARD1–NATH protein acetyltransferase complex, *Biochem. J.* 386 (2005) 433–443.
- [5] J.W. Jeong, M.K. Bae, M.Y. Ahn, S.H. Kim, T.K. Sohn, M.H. Bae, M.A. Yoo, E.J. Song, K.J. Lee, K.W. Kim, Regulation and destabilization of HIF-1 α by ARD1-mediated acetylation, *Cell* 111 (2002) 709–720.
- [6] T. Arnesen, X. Kong, R. Evjenth, D. Gromyko, J.E. Varhaug, Z. Lin, N. Sang, J. Caro, J.R. Lillehaug, Interaction between HIF-1 α (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 α , *FEBS Lett.* 579 (2005) 6428–6432.
- [7] T.A. Murray-Rust, N.J. Oldham, K.S. Hewitson, C.J. Schofield, Purified recombinant hARD1 does not catalyze acetylation of Lys532 of HIF-1 α fragments in vitro, *FEBS Lett.* 580 (2006) 1911–1918.
- [8] R. Bilton, N. Mazure, E. Trottier, M. Hattab, M.A. Dery, D.E. Richard, J. Pouyssegur, M.C. Brahimi-Horn, Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1 α and is not induced by hypoxia or HIF, *J. Biol. Chem.* 280 (2005) 31132–31140.
- [9] J.H. Lim, J.W. Park, Y.S. Chun, Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation, *Cancer Res.* 66 (2006) 10677–10682.
- [10] C.H. Yi, D.K. Sogah, M. Boyce, A. Degterev, D.E. Christofferson, J. Yuan, A genome-wide RNAi screen reveals multiple regulators of caspase activation, *J. Cell Biol.* 179 (2007) 619–626.
- [11] Z. Gao, D. Hwang, F. Bataille, M. Lefevre, D. York, M.J. Quon, J. Ye, Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex, *J. Biol. Chem.* 277 (2002) 48115–48121.
- [12] S. Lee, C. Andrieu, F. Saltel, O. Destaing, J. Auclair, V. Pouchkine, J. Michelon, B. Salaun, R. Kobayashi, P. Jurdic, E.D. Kieff, B.S. Sylla, IkappaB kinase beta phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation, *Proc. Natl. Acad. Sci. USA* 101 (2004) 17416–17421.
- [13] A. Di Cristofano, M. Niki, M. Zhao, F.G. Karnell, B. Clarkson, W.S. Pear, L. Van Aelst, P.P. Pandolfi, P62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl), *J. Exp. Med.* 194 (2001) 275–284.
- [14] M.C. Hu, D.F. Lee, W. Xia, L.S. Golfman, F. Ou-Yang, J.Y. Yang, Y. Zou, S. Bao, N. Hanada, H. Saso, R. Kobayashi, M.C. Hung, IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a, *Cell* 117 (2004) 225–237.
- [15] D.F. Lee, H.P. Kuo, C.T. Chen, J.M. Hsu, C.K. Chou, Y. Wei, H.L. Sun, L.Y. Li, B. Ping, W.C. Huang, X. He, J.Y. Hung, C.C. Lai, Q. Ding, J.L. Su, J.Y. Yang, A.A. Sahin, G.N. Hortobagyi, F.J. Tsai, C.H. Tsai, M.C. Hung, IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway, *Cell* 130 (2007) 440–455.
- [16] Y. Zou, H. Peng, B. Zhou, Y. Wen, S.C. Wang, E.M. Tsai, M.C. Hung, Systemic tumor suppression by the proapoptotic gene bik, *Cancer Res.* 62 (2002) 8–12.
- [17] J. Deng, S.A. Miller, H.Y. Wang, W. Xia, Y. Wen, B.P. Zhou, Y. Li, S.Y. Lin, M.C. Hung, Beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer, *Cancer Cell* 2 (2002) 323–334.
- [18] T. Arnesen, D. Gromyko, F. Pendino, A. Rynningen, J.E. Varhaug, J.R. Lillehaug, Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex, *Oncogene* 25 (2006) 4350–4360.
- [19] T.S. Fisher, S.D. Etages, L. Hayes, K. Crimin, B. Li, Analysis of ARD1 function in hypoxia response using retroviral RNA interference, *J. Biol. Chem.* 280 (2005) 17749–17757.
- [20] W.C. Huang, T.K. Ju, M.C. Hung, C.C. Chen, Phosphorylation of CBP by IKK α promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB, *Mol. Cell* 26 (2007) 75–87.